1. Scrip
  2. >>R&D
  3. >>Clinical Trials

GamaMabs’ Glyco-Engineered Murlentamab Shows Promise in Colorectal, Gynecological Cancers

 
• By Eleanor Malone

Murlentamab Phase II results indicate its potential for use in combination with chemotherapy or other immunological agents, to target AMHRII-expressing tumors.

Climb
Murlentamab could help other agents tackle cancer

A glyco-engineered antibody from French firm GamaMabs Pharma SA has demonstrated longer than expected progression-free survival rates in patients with metastatic colorectal cancer also treated with trifluridine/tipiracil (FTD/TPI – Lonsurf). The improvement was especially marked in patients with medium to high expression of anti-Müllerian hormone receptor II (AMHRII), which the antibody, murlentamab, is designed to target.

The Phase II results presented at the European Society of Medical Oncology World Congress on Gastrointestinal Cancer in Barcelona, Spain,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Discontinuations For Viking’s Oral Obesity Drug VK2735 Scare Investors

 
• By Joseph Haas

Analysts lauded the 13-week weight-reduction rates Viking’s oral dual GLP-1/GIP agonist showed in Phase II, but the firm’s stock tumbled 42% due to high discontinuation rates.

Interest In PTC’s Sephience Launch Overshadows FDA’s Vatiquinone Rejection

 
• By Alaric DeArment

PTC said it got a complete response letter for the Friedreich’s ataxia drug, with the agency asking for an additional clinical trial.

Boehringer Expands Eyecare Horizons With Palatin Collaboration

 
• By Andrew McConaghie

The German company already had four eye disease candidates in Phase II development and sees promise in Palatin’s novel melanocortin receptor modulators.

Egetis Eyes Swift US Submission For Emcitate

 
• By Kevin Grogan

The Sweden-based firm is set for talks with the FDA on the regulatory path for its MCT8 deficiency candidate.

More from R&D

Third Sickle Cell Product From Pfizer’s Global Blood Buyout Hits Snag

 
• By Alaric DeArment

The drugmaker reported a negative Phase III study for inclacumab, after a partial clinical hold for osivelotor and pulling Oxbryta from the market.

Pipeline Watch: Seven Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Tonix Ready To Revive Fibromyalgia Market With Tonyma

 
• By Joseph Haas

The first new drug for fibromyalgia since 2009, Tonyma is a reformulation of cyclobenzaprine intended for chronic therapy. Tonix said the drug targets non-restorative sleep.